Philippe Rougier
Impact in
- Hepatology top 0.05%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 0.02%
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
Papers in
- Hepatology 30
- Hepatocellular Carcinoma Treatment and Prognosis 29
- Oncology 101
- Colorectal Cancer Treatments and Studies 70
- Pancreatic and Hepatic Oncology Research 20
- Cancer Treatment and Pharmacology 16
- Co-authors
- Eric Van CutsemBernard NordlingerClaus-Henning KöhneMichael SchlichtingGunnar FolprechtChristophe PennaG. BodokyMichel Ducreux
In The Last Decade
Philippe Rougier
125 papers receiving 21.9k citations
Hit Papers
Peers
Comparison fields: 5 of 136
- Hepatology 6.6k
- Oncology 17.4k
- Pathology and Forensic Medicine 4.1k
- Pulmonary and Respiratory Medicine 7.4k
- Cancer Research 2.7k
Countries citing papers authored by Philippe Rougier
This map shows the geographic impact of Philippe Rougier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Rougier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Rougier more than expected).
Fields of papers citing papers by Philippe Rougier
This network shows the impact of papers produced by Philippe Rougier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Rougier. The network helps show where Philippe Rougier may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Philippe Rougier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer Hit paper breakdown → | 2015 | 578 |
| 2 | 2014 | 8 | |
| 3 | 2013 | 1 | |
| 4 | 2012 | 163 | |
| 5 | Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status Hit paper breakdown → | 2011 | 1441 |
| 6 | 転移性大腸癌のファーストライン治療としてのセツキシマブ+イリノテカン,フルオロウラシルおよびロイコボリン: 腫瘍KRASとBRAF突然変異ステータスによる全生存率分析の最新版 | 2011 | 61 |
| 7 | 2011 | 18 | |
| 8 | 2010 | 85 | |
| 9 | Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial Hit paper breakdown → | 2009 | 487 |
| 10 | Analysis of PTEN , BRAF , and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer Hit paper breakdown → | 2009 | 529 |
| 11 | 2009 | 30 | |
| 12 | KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab Hit paper breakdown → | 2008 | 1141 |
| 13 | 2008 | 123 | |
| 14 | Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Hit paper breakdown → | 2008 | 1396 |
| 15 | 2007 | 18 | |
| 16 | 2006 | 33 | |
| 17 | 2006 | 433 | |
| 18 | Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases Hit paper breakdown → | 2005 | 527 |
| 19 | Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Hit paper breakdown → | 1998 | 786 |
| 20 | 1992 | 23 |
About Philippe Rougier
Philippe Rougier is a scholar working on Hepatology, Oncology, Gastroenterology, Pulmonary and Respiratory Medicine and Neurology, having authored 128 papers that have together received 22.4k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (70 papers), Gastric Cancer Management and Outcomes (30 papers), Hepatocellular Carcinoma Treatment and Prognosis (29 papers), Pancreatic and Hepatic Oncology Research (20 papers), Neuroendocrine Tumor Research Advances (20 papers), Genetic factors in colorectal cancer (18 papers), Neuroblastoma Research and Treatments (17 papers) and Cancer Treatment and Pharmacology (16 papers). The work is most often cited by research in Hepatology (6.6k citations), Oncology (17.4k citations), Pathology and Forensic Medicine (4.1k citations), Pulmonary and Respiratory Medicine (7.4k citations) and Cancer Research (2.7k citations). Philippe Rougier has collaborated with scholars based in France, Belgium and Germany. Frequent co-authors include Eric Van Cutsem, Bernard Nordlinger, Claus-Henning Köhne, Michael Schlichting, Gunnar Folprecht, Christophe Penna, G. Bodoky, Michel Ducreux, Pierre Laurent‐Puig and Jean‐Baptiste Bachet. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, The Lancet Oncology, Cancer and Digestive and Liver Disease.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.